Drug Type Antibody drug conjugate (ADC) |
Synonyms MK 2140, MK-2140, VLS-101 |
Target |
Action antagonists, inhibitors |
Mechanism ROR1 antagonists(Inactive tyrosine-protein kinase transmembrane receptor ROR1 antagonists), Tubulin inhibitors |
Therapeutic Areas |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationFast Track (United States), Orphan Drug (United States) |



| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Diffuse Large B-Cell Lymphoma | Phase 3 | United Kingdom | 14 Jan 2022 | |
| Diffuse large B-cell lymphoma recurrent | Phase 3 | United States | 14 Jan 2022 | |
| Diffuse large B-cell lymphoma recurrent | Phase 3 | China | 14 Jan 2022 | |
| Diffuse large B-cell lymphoma recurrent | Phase 3 | Japan | 14 Jan 2022 | |
| Diffuse large B-cell lymphoma recurrent | Phase 3 | Argentina | 14 Jan 2022 | |
| Diffuse large B-cell lymphoma recurrent | Phase 3 | Australia | 14 Jan 2022 | |
| Diffuse large B-cell lymphoma recurrent | Phase 3 | Brazil | 14 Jan 2022 | |
| Diffuse large B-cell lymphoma recurrent | Phase 3 | Canada | 14 Jan 2022 | |
| Diffuse large B-cell lymphoma recurrent | Phase 3 | Chile | 14 Jan 2022 | |
| Diffuse large B-cell lymphoma recurrent | Phase 3 | Colombia | 14 Jan 2022 |
Phase 2 | Diffuse Large B-Cell Lymphoma First line | 36 | Zilovertamab Vedotin+R-CHP (1.75 mg/kg) | txvlehkskv(klnvvhfuyt) = 25% jwffbdlalw (dblnxbjrsk ) View more | Positive | 11 Sep 2026 | |
Zilovertamab Vedotin+R-CHP (2.0 mg/kg) | |||||||
Phase 2/3 | 40 | Zilovertamab Vedotin + R-GemOx | oxpejlffbc(pcbcxfqosn) = qxocmxbbet mxpdpxqyxy (btstwakxhr ) View more | Positive | 11 Sep 2026 | ||
Zilovertamab Vedotin + R-GemOx (ZV 1.5 mg/kg) | ylcsjbcdqz(ylxatvfxuf) = ompgfnpqtj eupjiujybi (yfjkgiyium ) View more | ||||||
Phase 3 | Diffuse Large B-Cell Lymphoma First line | 1,046 | Zilovertamab vedotin + R-CHP | wdbfxoisyc(qzinjkyfmf) = cvtnoxhwfn zwpawfdepd (hcipmwakop ) | Positive | 06 Dec 2025 | |
R-CHOP | uzvtmrvfez(nfadscimhr) = bbmzhohytc hifguxmdcl (sulgsoixaq ) | ||||||
Phase 2 | Diffuse Large B-Cell Lymphoma First line | 36 | Zilovertamab vedotin 1.75 mg/kg + R-CHP | ryztnbbgjl(obxocqrcok) = 25% yqcqvnwvwj (awbrsphhyl ) View more | Positive | 06 Dec 2025 | |
Zilovertamab vedotin 2.0 mg/kg + R-CHP | |||||||
Phase 2 | 594 | Zilovertamab vedotin plus R-CHP | gbwckyyjmz(uvbnzbpvzx) = occurred in 53% and 58% of pts in the Zilovertamab vedotin plus R-CHP and polatuzumab vedotin plus R-CHOP arms, respectively. xbdzshyavi (sqsmhznwhe ) | Positive | 06 Dec 2025 | ||
Phase 3 | Diffuse Large B-Cell Lymphoma First line | 1,046 | Zilovertamab vedotin + R-CHP | cmltosbjnh(kwrmxgrrhe) = axbpahwtnz xaamwkfsdn (gclhvjggdn ) | Positive | 10 Sep 2025 | |
R-CHOP | cmltosbjnh(kwrmxgrrhe) = glsxyfexim xaamwkfsdn (gclhvjggdn ) | ||||||
Phase 2/3 | 40 | kbstswxdpt(sdofkvtmag) = eeiivfyqfu vdibbmvfxw (enhowlxaav ) View more | Positive | 17 Jun 2025 | |||
pkufyuzbpv(xjefinkgbb) = btysjcgohk tptlloaziv (jltxzddqwq ) View more | |||||||
Phase 2/3 | 40 | nsikodidcr(bwxffizehd) = glkhbwihwa hipcuqtwyr (wuhprnbtnn ) View more | Positive | 04 Jun 2025 | |||
nsikodidcr(bwxffizehd) = yoblwovpro hipcuqtwyr (wuhprnbtnn ) View more | |||||||
Phase 2/3 | 40 | ssvlsppkrh(ruqnoybisg) = 1.75 mg/kg bdanyxphbb (xpwarsfvcv ) View more | Positive | 30 May 2025 | |||






